Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Cash (2020 - 2025)

SAB Biotherapeutics' Change in Cash history spans 6 years, with the latest figure at -$18.9 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 6825.84% year-over-year to -$18.9 million; the TTM value through Dec 2025 reached $1.6 million, up 103.37%, while the annual FY2025 figure was $1.6 million, 103.37% up from the prior year.
  • Change in Cash reached -$18.9 million in Q4 2025 per SABSW's latest filing, down from $25.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $54.1 million in Q4 2023 to a low of -$42.5 million in Q1 2024.
  • Average Change in Cash over 5 years is -$105385.2, with a median of -$2.6 million recorded in 2023.
  • Peak YoY movement for Change in Cash: skyrocketed 33841.08% in 2021, then crashed 6825.84% in 2025.
  • A 5-year view of Change in Cash shows it stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.3% to $54.1 million in 2023, then plummeted by 100.5% to -$273209.0 in 2024, then plummeted by 6825.84% to -$18.9 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Change in Cash are -$18.9 million (Q4 2025), $25.7 million (Q3 2025), and -$1.9 million (Q2 2025).